Shareholders are investing 8.3 million Euro in the expanding business–Rainer Hepberger new CFO–Phase III study begins for ICES13
B3C newswire, 04/27/2012
In order to continue on its agreed expansion course, the Austrian biotechnology company Innovacell is acquiring fresh capital: shareholders in the firm, which is developing cell–therapy for the treatment of stress–urinary incontinence (ICES13) and faecal incontinence, have agreed on a capital expansion of 8.3 million Euro. This will take effect in two tranches. The main shareholders are the financial investors Buschier, Fides, HYBAG und the private equity firm, uni venture.